Visintin et al. [39] reported that anti-TM4SF1 antibody conjugated with an auristatin cytotoxic agent shows anticancer activity in NSCLC, pancreatic, prostate, and colon cancers. This evidence concerns the gene TM4SF1 and non-small cell lung carcinoma.